KIN
Kindred Biosciences, Inc. [KIN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KIN Stock Summary
In the News
KIN Financial details
Company Rating
-
Market Cap
0
Income
-43.62M
Revenue
7.93M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
05 Aug 2021
P/E
-15.38
Forward P/E
-
PEG
4.61
P/S
-
P/B
5.39
P/C
-
P/FCF
-
Quick Ratio
8.56
Current Ratio
9.08
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.06
EPS next Y
-
EPS next Q
-
EPS this Y
-62.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
47.68%
EPS Q/Q
-12.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-25%
ROE
-32%
ROC
-0.22%
Gross Margin
89%
Oper. Margin
-47%
Profit Margin
-56%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.24-9.26
52W High
+2.78%
52W Low
+2.78%
RSI
-
Rel Volume
0.12
Avg Volume
1.51M
Volume
178.5K
Perf Week
0%
Perf Month
0%
Perf Quarter
0%
Perf Half Y
0%
-
-
-
-
Beta
1.31522
-
-
Volatility
0%, 0%
Prev Close
0%
Price
9.25
Change
0.11%
Company Profile
- Volume Average 1.51M
- Employee 63
- CEO Dr. Richard Chin
- Headquarters Burlingame,CALIFORNIA,US
- IPO Date 2013-12-12
-
Website
http://www.kindredbio.com 
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
